Recurrent COVID-19 in a patient with Good′s syndrome: a case report and literature review
10.3760/cma.j.cn112138-20241022-00704
- VernacularTitle:Good综合征合并反复新型冠状病毒感染1例并文献复习
- Author:
Yingli YANG
1
;
Ting ZHANG
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院中医科，北京100730
- Publication Type:Journal Article
- Keywords:
Immunodeficiency;
COVID-19;
Good′s syndrome
- From:
Chinese Journal of Internal Medicine
2025;64(7):680-684
- CountryChina
- Language:Chinese
-
Abstract:
We herein report a case of recurrent coronavirus disease 2019 (COVID-19) in a 56-year-old female with Good′s syndrome (GS) at Peking Union Medical College Hospital in April 2024. The patient was previously treated with thymectomy for thymoma and her immunoglobulin assays and lymphocyte subset analysis confirmed an immunocompromised state characterized predominantly by humoral immunodeficiency, consistent with a diagnosis of GS. Clinical symptoms improved following two courses of nirmatrelvir/ritonavir and four courses of molnupiravir, administered alongside adjunctive glucocorticoids and regular intravenous immunoglobulin (IVIG) supplementation. By the end of August 2024, a review of the literature identified 40 reported cases of COVID-19 in patients with GS worldwide. Among them, 25 met the diagnostic criteria for severe or critical illness, and 12 experienced persistent or relapsing infections. Antiviral therapy was administered in approximately half of the cases, most commonly for a 5-day course. However, four patients required prolonged or multi-target antiviral regimens due to persistent or relapsing infection, with the longest duration reported at 20 days. Convalescent plasma or monoclonal antibodies were used in 15 patients, and adjunctive glucocorticoids in 13. The vast majority received regular IVIG supplementation. Ten patients (25%) with GS and COVID-19 died. Patients with GS are susceptible to prolonged or recurrent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are at increased risk of severe disease and mortality due to impaired antibody production. Upon diagnosis of GS, IVIG therapy should be initiated. In the context of COVID-19, potential treatment strategies include extended multi-agent antiviral therapy guided by viral load, use of convalescent plasma (where available), and glucocorticoids tailored to disease severity. Further research is needed to define the optimal duration and combination of antiviral and immunomodulatory therapies in this population.
